Assembly Biosciences (ASMB) Stock Price, News & Analysis

Company Overview

Assembly Biosciences, Inc. (NASDAQ: ASMB) is a clinical-stage biotechnology company dedicated to the discovery, development and commercialization of novel therapies for hepatitis B virus (HBV) and hepatitis D virus (HDV) infections. The company’s core expertise lies in small-molecule modulation of viral proteins and host-targeted pathways to achieve sustained viral suppression and potential functional cure. Assembly’s research model integrates medicinal chemistry, structural biology and translational virology to advance its pipeline from early discovery through clinical development.

The company’s lead programs include core protein allosteric modulators (CpAMs) designed to disrupt the HBV lifecycle by interfering with capsid assembly and viral DNA replication, as well as prenylation inhibitors targeting the HDV lifecycle. Vebicorvir (ABI-H0731), a next-generation CpAM, is being studied in combination regimens to assess its ability to reduce surface antigen levels and achieve durable viral control. Assembly is also advancing ABI-H2158, an oral antiviral with broad potential to enhance host immune response and further suppress viral replication in chronic HBV patients.

Assembly conducts multi-center clinical trials across North America, Europe and Asia, collaborating with academic centers and global research networks to evaluate its candidates in diverse patient populations. The company operates its headquarters in Boulder, Colorado, with additional research activities in Cambridge, Massachusetts. Its management team brings extensive experience in antiviral drug development, leveraging prior success in hepatitis and oncology therapeutic programs.

Since its inception in 2015, Assembly has grown through strategic partnerships and in-licensing agreements, establishing a robust intellectual property portfolio around core modulation and prenylation inhibition. The company continues to engage regulatory authorities worldwide with the goal of delivering new, safe and effective treatment options for patients living with chronic HBV and HDV infections.

Key Stats

• Today's Range: $27.83 to $29.78
• 50-Day Range: $26.33 to $29.95
• 52-Week Range: $11.64 to $39.71
• Volume: 534,655 shs
• Average Volume: 113,138 shs
• Market Capitalization: $469.55 million
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: $42.75
• Consensus Rating: Moderate Buy

Assembly Biosciences Stock Analysis - MarketRank™

Assembly Biosciences scored higher than 39% of companies evaluated by MarketBeat, and ranked 625th out of 856 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 3.9 / 5
• Analyst Rating: Moderate Buy

Consensus Rating

Assembly Biosciences has received a consensus rating of Moderate Buy. The company's average rating score is 2.57, and is based on no strong buy ratings, 5 buy ratings, 1 hold rating, and 1 sell rating.

Upside Potential

Assembly Biosciences has a consensus price target of $42.75, representing about 44.7% upside from its current price of $29.55.

Amount of Analyst Coverage

Assembly Biosciences has only been the subject of 3 research reports in the past 90 days.

Earnings and Valuation

• Score: 0.0 / 5
• Proj. Earnings Growth: Decreasing

Earnings Growth

Earnings for Assembly Biosciences are expected to decrease in the coming year, from ($0.93) to ($2.28) per share.

Price to Book Value per Share Ratio

Assembly Biosciences has a P/B Ratio of 2.27. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities.

Short Interest

• Score: 1.0 / 5
• Short Interest Level: Bearish

Percentage of Shares Shorted

10.19% of the float of Assembly Biosciences has been sold short.

Short Interest Ratio / Days to Cover

Assembly Biosciences has a short interest ratio ("days to cover") of 16.41, which indicates bearish sentiment.

Change versus previous month

Short interest in Assembly Biosciences has recently decreased by 0.14%, indicating that investor sentiment is improving.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

Assembly Biosciences does not currently pay a dividend.

Dividend Growth

Assembly Biosciences does not have a long track record of dividend growth.

News and Social Media

• Score: 3.2 / 5
• News Sentiment: 0.20

News Sentiment

Assembly Biosciences has a news sentiment score of 0.20. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.59 average news sentiment score of Medical companies.

News Coverage This Week

MarketBeat has tracked 4 news articles for Assembly Biosciences this week, compared to 3 articles on an average week.

Search Interest

1 people have searched for ASMB on MarketBeat in the last 30 days.

MarketBeat Follows

1 people have added Assembly Biosciences to their MarketBeat watchlist in the last 30 days.

Company Ownership

• Score: 0.4 / 5
• Insider Trading: N/A

Insider Buying vs. Insider Selling

In the past three months, Assembly Biosciences insiders have not sold or bought any company stock.

Percentage Held by Insiders

5.10% of the stock of Assembly Biosciences is held by insiders.

Percentage Held by Institutions

19.92% of the stock of Assembly Biosciences is held by institutions.

ASMB Stock Analysis - Frequently Asked Questions

How have ASMB shares performed this year?

Assembly Biosciences' stock was trading at $34.01 at the beginning of the year. Since then, ASMB stock has decreased by 13.1% and is now trading at $29.55.

How were Assembly Biosciences' earnings last quarter?

Assembly Biosciences, Inc. (NASDAQ:ASMB) posted its earnings results on Thursday, March, 19th. The biopharmaceutical company reported $2.48 EPS for the quarter, topping the consensus estimate of ($0.51) by $2.99. The biopharmaceutical company earned $42.47 million during the quarter, compared to analyst estimates of $7.42 million. Assembly Biosciences had a negative net margin of 8.47% and a negative trailing twelve-month return on equity of 5.63%.

When did Assembly Biosciences' stock split?

Shares of Assembly Biosciences reverse split on Monday, February 12th 2024.The 1-12 reverse split was announced on Monday, February 12th 2024. The number of shares owned by shareholders was adjusted after the closing bell on Monday, February 12th 2024. An investor that had 100 shares of stock prior to the reverse split would have 8 shares after the split.

When did Assembly Biosciences IPO?

Assembly Biosciences (ASMB) raised $19 million in an IPO on Thursday, December 16th 2010. The company issued 2,900,000 shares at $6.00-$7.00 per share.

How do I buy shares of Assembly Biosciences?

Shares of ASMB stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

What other stocks do shareholders of Assembly Biosciences own?

Based on aggregate information from My MarketBeat watchlists, some other companies that Assembly Biosciences investors own include Waste Connections (WCN), Voyager Therapeutics (VYGR), DiamondRock Hospitality (DRH), AUO (AUOTY), American Water Works (AWK), The RMR Group (RMR) and iShares Micro-Cap ETF (IWC).

Company Calendar

• Last Earnings: 3/19/2026
• Today: 5/05/2026
• Next Earnings (Estimated): 5/07/2026
• Fiscal Year End: 12/31/2026

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Medical
• Industry: MED - GENERIC DRG
• Sub-Industry: Pharmaceuticals
• Current Symbol: NASDAQ:ASMB
• CIK: 1426800
• Web: www.assemblybio.com
• Phone: (833) 509-4583
• Fax: 646-706-5101
• Employees: 100
• Year Founded: 2005

Price Target and Rating

• Average Price Target for Assembly Biosciences: $42.75
• High Price Target: $50.00
• Low Price Target: $38.00
• Potential Upside/Downside: +44.7%
• Consensus Rating: Moderate Buy
• Rating Score (0-4): 2.57
• Research Coverage: 7 Analysts

Profitability

• EPS (Trailing Twelve Months): ($0.74)
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: -$6.12 million
• Net Margins: -8.47%
• Pretax Margin: -8.47%
• Return on Equity: -5.63%
• Return on Assets: -3.62%

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: 5.22
• Quick Ratio: 5.22

Sales & Book Value

• Annual Sales: $72.30 million
• Price / Sales: 6.49
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: $13.04 per share
• Price / Book: 2.27

Miscellaneous

• Outstanding Shares: 15,890,000
• Free Float: 15,082,000
• Market Cap: $469.55 million
• Optionable: Optionable
• Beta: 1.08